Immitra Bio logoImmitra Bio
A new class of genetic medicine

Unlock Hidden Biology

7000+ rare genetic diseases affect 400 million people worldwide. 95% lack therapy, 50% are children. We seek solutions within the vast redundancy already present in the human genome.

Our mission

In-vivo
Scalable
Gene
Editing
Platform

Today's approved stem cell therapies for genetic disorders are toxic, unscalable, slow, and expensive, all rooted in ex-vivo approaches. We're developing an in-vivo alternative, a single, off-the-shelf injection that cures patients without chemotherapy or cell transplantation. Accessible to all patients worldwide and independent of their genetic mutations, no patient will be left behind.

Read More News
21 July 2026 - Company Announcement

Immitra Bio Secures CHF 2.4 M/ USD 3M in Pre-Seed Funding to Advance Its Scalable In-Vivo Gene Editing Platform and Lead Asset

Immitra Bio announced the successful completion of an upsized CHF 2.4 million pre-seed financing round. CHF 2.25 million was provided by venture capital and private investors, with an additional CHF 150k secured through non-dilutive funding sources. The round was led by Backbone Ventures and co-led by OCCIDENT with participation from Another VC, Kickfund, Venture Kick, Zürcher Kantonalbank, FONGIT, ETH Foundation, and select private investors.
Read more

15 June 2026 - Venture Kick Stage III

Immitra Bio receives CHF 150,000 from Venture Kick to advance in-vivo stem cell therapy

Immitra Bio GmbH has secured CHF 150,000 in Venture Kick Stage III funding to develop a new treatment approach for rare genetic diseases. The ETH Zürich spin-off is developing an in-vivo stem cell therapy platform that aims to replace complex transplants with a single off-the-shelf treatment, initially targeting severe inherited red blood cell disorders. With the Stage III funding, Immitra Bio will advance preclinical proof of concept studies, validate its in-vivo stem cell therapy platform, and demonstrate disease reversal in relevant models.
Read more

29 May 2026 - TOP100 Swiss Startup Award

Immitra Bio shortlisted for the TOP100 Swiss Startup Award 2026 Public Voting

Immitra Bio has been shortlisted for the TOP100 Swiss Startup Award 2026 Public Voting, recognizing promising Swiss startup newcomers selected by a jury of leading investors and startup experts. The public vote will help decide which startups take the stage at the TOP100 Award Night 2026, where the TOP100 Newcomer of the Year will be crowned.

Support Immitra Bio by visiting our startup profile and voting through the official TOP100 public voting platform. Each person can vote for one startup only, and voting closes on 19 July 2026 at midnight.
Vote now

30 Apr 2026 - Gebert Rüf Stiftung

Immitra Bio wins 150'000 CHF Innobooster funding supported by Gebert Rüf Stiftung

Gebert Rüf Stiftung supports high-potential businesses from the Venture Kick program with the aim of substantially accelerating their market entry. The funding line is calling for top talents with convincing applications of how a research & development or design boost can speed up a successful market penetration of their deeptech business.
Read more

08 Dec 2025 - Forbes

Our CEO, Jan Nelis, Recognized Among Forbes 30Under30 Swiss Innovators

Forbes 30Under30, the annual premier list that presents influential personalities in Switzerland, Germany, and Austria who positively impact business and society. Selected from startups offering solutions in various sectors and prominent figures supporting the ecosystem.
Read more

Rethinking the given

Utilize inherent potential

Our biological blueprint is layered with echoes and redundancies, an untapped pool of information waiting to be exploited.

Redundancy is not noise, it is a reserve
Life is written in repetitions and shadows of itself , an unused reserve of code waiting to be called upon when systems fail. Beneath the visible layer, parallel possibilities remain intact, hinting that repair may come not from outside, but from what has always been there.
Meet the team

Leadership and scientific team

We are building at the frontier of biology and engineering, turning fundamental discoveries into new therapeutic possibilities.

Translational Top-tier academic and industry expertise combined to translate ideas into once-and-done genomic medicine.
Founder-Led Combining deep scientific expertise with disciplined execution to translate breakthrough research into real-world impact.

Jan Nelis

Co-founder and Chief Executive Officer

Driving vision and strategy at Immitra Bio, translating a bold scientific thesis into a scalable company.

Amir Taheri

Co-founder and Chief Scientific Officer

Seasoned gene editing expert with extensive experience in the pharmaceutical industry.

Jacob Corn

Co-founder and Scientific Advisor

Key Opinion Leader in cutting-edge CRISPR-Cas9 technologies, Genome Biology Professor at ETH Zurich.

Veera Vainio

R&D Scientist

Cell and Molecular Biologist, experienced with characterization of proteins and their function, ETH Zurich alumni.

Marine Laurent

R&D Scientist

Cell and Molecular Biologist, hematopoietic stem cell engineering expert, Genethon alumni.

We are a multidisciplinary team spanning gene editing, computational biology, and translational medicine, united by a shared goal to make genetic therapies more precise, scalable, and accessible.
Institutional backing

Backed by leading institutions

Supported by a growing network of leading investors and research partners.